-
Mashup Score: 231How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement - 9 month(s) ago
Reimbursement is a key factor in defining which resources are made available to ensure quality, efficiency, availability, and access to specific health-care interventions. This Policy Review assesses publicly funded radiotherapy reimbursement systems in Europe. We did a survey of the national societies of radiation oncology in Europe, focusing on the general features and global structure of the reimbursement system, the coverage scope, and level for typical indications. The annual expenditure covering radiotherapy in each country was also collected.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 46CONGRESO SOCHIRA 2024 | SOCHIRA - 9 month(s) ago
Con mucho agrado anunciamos la “XVIII Congreso Sociedad Chilena de Radioterapia Oncologica” a desarrollarse entre los d í as 11 y 14 de Abril 2024 en Hotel Cumbres de San Pedro de Atacama, Chile. La jornada contar á con la participaci ó n de especialistas en diversas á reas de inter é s a nivel nacional e internacional, orientado principalmente a m é dicos onc ó logos radioterapeutas, tecn ó logos m é dicos, f í sicos m é dicos, y otros profesionales especialistas que trabajan en radioterapia, resultando
Source: www.sochira.clCategories: General Medicine News, Oncologists2Tweet-
😎 Super excited to be invited to 🇨🇱@SochiraCl 2024 #radonc congress, https://t.co/vnrFuSlLT0, in the desert 🌵of San Pedro de Atacama 🌶️!! Thanks 🙏🏽for the outstanding hosting by @clau_carvajal_, @pablomunozsch, Evelyn San Martin and @hletelier! Dusting off my Spanish…..🙈 😵💫 https://t.co/gw4no0jlXI
-
-
Mashup Score: 18
Our findings suggests that systematic endoscopic mediastinal staging in patients with locally advanced or unresectable NSCLC is more accurate than PET alone in defining extent of mediastinal involvement. Standard guideline-recommended PET-based radiotherapy planning results in suboptimal tumour coverage. Our findings indicate that systematic endoscopic staging should be routinely performed in patients with locally advanced NSCLC being considered for radiotherapy to accurately inform radiation planning and treatment decision making in patients with locally advanced NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
3/ n=155, in 37% PET/EBUS was discordant – 12% ⬆️ disease, 25% ⬇️ disease extent. When upstaged with EBUS, missed lymph nodes get only ~10% of prescribed dose. We suggest use of systematic EBUS routinely before #radiotherapy. https://t.co/KCdkUIKk9Z
-
-
Mashup Score: 15Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases - 10 month(s) ago
Medical operability is prognostic for survival after SABR in primary malignancies. This study investigated the prognostic significance of medical oper…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
We use a similar approach to @ChadTangMD in @PeterMacRadOnc @gu_onc #radonc. We often use SABR alone upfront in oligometastases. We reported a 3- and 5-year freedom from systemic therapy of 40% and 31% with this approach here (n=401, basket histology); https://t.co/7nnDpccrwM https://t.co/SQinSj9n2J https://t.co/AmjE04368P
-
-
Mashup Score: 239Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial - 11 month(s) ago
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surg…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
1/ For #KidneyCancerAwareness month @TheLancetOncol has a 50-day full link to @TROGfightcancer FASTRACK II! https://t.co/p5SVg9Ktvl. Thank you @CancerAustralia, @ANZUPtrials, @VarianMedSys. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc
-
-
Mashup Score: 22
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostShankar Siva@_ShankarSiva1/ Thank you patients, families, trial staff and investigators for participating in @TROGfightcancer 15.03 FASTRACK II! This trial recruited n=70 across 8 sites in and #ASTRO23! #radonc #kcsm #radiotherapy @ANZUPtrials@KidneyCancerAlison Tree and 9 others5:35 PM · Oct 1, 202373.8K…
Source: x.comCategories: General Medicine News, Oncologists2Tweet-
4/ Very excited to share this with you!!! @montypal @DrChoueiri @KidneyCancerDoc @grantissimus @drphil_urology @wandering_gu @uretericbud @spsutkaMD @MichaelStaehler @IKCCorg @KidneyCancer For more information, please follow the thread from @ASTRO 2023. https://t.co/eD4ebajVaZ
-
-
Mashup Score: 28
Surgery is the standard of care for patients with primary renal cell carcinoma. Stereotactic body radiotherapy (SBRT) is a novel alternative for patients who are medically inoperable, technically high risk, or who decline surgery. Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. This systematic review was performed to assess the safety and efficacy of SBRT for primary renal cell carcinoma. Review results then formed the basis for the practice guidelines described, on behalf of the International Stereotactic Radiosurgery Society.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
3/ There are >dozen clinical trials of SABR for primary RCC – outlined in @ISRSy practice guideline - https://t.co/ih9Fr6gSG8 – compared to zero for thermal ablation. The weight of evidence is with SABR, not TA, and is arguably the preferred modality for non-surgical therapy
-
-
Mashup Score: 219Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial - 11 month(s) ago
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surg…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
1/ For #KidneyCancerAwareness month @TheLancetOncol has a 50-day full link to @TROGfightcancer FASTRACK II! https://t.co/p5SVg9Ktvl. Thank you @CancerAustralia, @ANZUPtrials, @VarianMedSys. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc
-
-
Mashup Score: 63Some Like It Hot: The Value of Dose and Hot Spots in Lung Stereotactic Body Radiation Therapy - 11 month(s) ago
It has been nearly 20 years since Onishi et al published the pivotal analysis showing that early-stage non-small cell lung cancers (ES-NSCLC) receiving a biologically effective dose (BED)10 ≥100 Gy at the isocenter had improved local control (LC).1 Prospective lung stereotactic body radiation therapy (SBRT) trials have demonstrated a 5-year LC of 90% to 96% in ES-NSCLC.2,3 However, retrospective series with longer follow-up indicate that the risk of local recurrence may be higher and may be related to how lung SBRT is prescribed.
Source: www.redjournal.orgCategories: General Medicine News, Oncologists2Tweet-
Some like it hot! See oncoscan commentary on the subject ➡️ https://t.co/sx00Hp5jSF @DrewMoghanaki @UCD_radonc @TimothyKruserMD @MeredithGiulia1 @IJROBP 🐺#radonc https://t.co/CONkCboQ0S
-
-
Mashup Score: 61Some Like It Hot: The Value of Dose and Hot Spots in Lung Stereotactic Body Radiation Therapy - 11 month(s) ago
It has been nearly 20 years since Onishi et al published the pivotal analysis showing that early-stage non-small cell lung cancers (ES-NSCLC) receiving a biologically effective dose (BED)10 ≥100 Gy at the isocenter had improved local control (LC).1 Prospective lung stereotactic body radiation therapy (SBRT) trials have demonstrated a 5-year LC of 90% to 96% in ES-NSCLC.2,3 However, retrospective series with longer follow-up indicate that the risk of local recurrence may be higher and may be related to how lung SBRT is prescribed.
Source: www.redjournal.orgCategories: General Medicine News, Oncologists2Tweet-
Some like it hot! See oncoscan commentary on the subject ➡️ https://t.co/sx00Hp5jSF @DrewMoghanaki @UCD_radonc @TimothyKruserMD @MeredithGiulia1 @IJROBP 🐺#radonc https://t.co/CONkCboQ0S
-
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - https://t.co/qyAG8X6Rdq “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer https://t.co/yxqNP9FEkA